Streamline Your Path to Reimbursement
Helix Life Sciences helps you navigate the complexities of Swiss market access, accelerating your time to reimbursement and maximizing patient access to your life-changing therapies.
The Swiss healthcare system offers a robust market for innovative medical solutions. However, securing reimbursement for your product requires a strategic approach that considers the intricacies of the Swiss specialties list (SL) and FOPH pricing framework.
![](https://www.helix-lifesciences.ch/wp-content/uploads/2024/07/Market_access_pricing_reimbursement.jpeg)
- Our Capabilities
Your Swiss Market Access Partner
Value Communication
We help you develop a data-driven value story that effectively communicates the clinical and economic benefits of your product to FOPH, maximizing your chance of securing optimal reimbursement.
Navigate FOPH Requirements & Secure Coverage
Our experts guide you through crafting a compelling dossier and HTA strategy that meets FOPH (Federal Office of Public Health) standards for SL (specialties list) inclusion and coverage.
Managed Entry Agreement (MEA) Support
We help you navigate the MEA process, exploring options like price-volume agreements or performance-based models, to address specific challenges and secure market access for innovative therapies.
- Client Goals
Accelerating Market Access for the Swiss Market
Our goal is to ensure your product receives a favorable decision from FOPH, granting it inclusion on the Swiss specialties list and securing optimal reimbursement.
Our team of market access experts cuts through complexities to expedite the FOPH process, ensuring your therapy reaches patients quickly. Your goal is to minimize time to market and maximize patient access, while achieving a favorable reimbursement decision from FOPH
We craft a data-driven value story supported by real-world data (RWD) and real-world evidence (RWE) that goes beyond clinical trial results.
Discover our market access offerings:
SL & HTA Strategy:
- Craft winning submissions for Swiss specialties list (SL) inclusion.
- Develop a targeted Health Technology Assessment (HTA) strategy.
- Secure coverage for your innovative therapy.
Compelling Value Story:
- Translate clinical data into real-world impact for FOPH.
- Leverage real-world data (RWD) & real-world evidence (RWE).
- Maximize reimbursement potential.
Managed Entry Agreement (MEA) Support:
- Explore options like price-volume agreements or performance-based models.
- Address specific challenges for market access.
- Unlock access for innovative therapies with uncertain value propositions.
Post-Launch Reimbursement Management:
- Maintain optimal product positioning within the Swiss market.
- Monitor and respond to changes in FOPH regulations.
- Ensure long-term access for your therapy.
Digital Health Market Access:
- Understand reimbursement pathways for Digital Health solutions
- Consider the best options for a sustainable go-to-market strategy
- Establish a mature outcomes data collection practice to demonstrate long term product value
Start Your Journey with Helix
Drop your contact details into the form, and we’ll reach out to you!
Get started
Schedule Your Consultation Today
![](https://www.helix-lifesciences.ch/wp-content/uploads/2023/12/Group-124-2.png)
Start
Your
Journey
With Helix.
Drop your contact details into the form, and we’ll reach out to you!